| To: Area51 who wrote (30) | 1/29/2019 9:39:52 AM | | From: Kirk © | | | | Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare
- - The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation
- - BEST democratizes financing through targeted investments for specific therapeutic drug products
LEXINGTON, Mass., Jan. 29, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare. Tokenization will enable qualified investors to directly invest in a single biotech product while preserving shareholder equity.
The growing adoption of blockchain technology, together with the latest financial regulatory changes, offers new alternatives to fund selected products with digital securities and opens an unprecedented opportunity to target financial investments in pharmaceutical product development.
"Today, by announcing the first of its kind asset backed digital security offering in healthcare, we open the doors for a transformative financing vehicle," said Garo Armen, Chairman and CEO of Agenus. "We believe this unique structure will pave the way for allowing targeted investment by qualified investors in the development of therapeutic products. This instrument, powered by blockchain technology, enables us to revolutionize the financing of drug development."
Each token to be issued will represent a portion of potential future US sales of AGEN2034, Agenus' anti-PD-1 antibody, now in pivotal clinical trials, and is entitled to a defined return claimable through token-by-token redemption starting with the first US commercial sale of AGEN2034. Qualified investors will be eligible to purchase BEST securities under preferred terms in the initial stage of the Digital Security Offering. Investments into this unique financing mechanism of up to $100M will accelerate the development, commercialization, distribution, and indication expansion for anti-PD-1, AGEN2034.
This type of innovation directly links Agenus' mission of speeding the development of immuno-oncology therapies, advancing more combination trials, and expanding its reach to additional indications. The company's recently announced collaboration with Gilead provides $150M in up-front cash and approximately $1.7 Billion in future fees and milestones to fund activities. Introducing BEST expands its product specific financing options for drug development while providing investors with an attractive risk-return profile.
Agenus anticipates the industry will adopt this financing model as an attractive means of obtaining capital in coming years. BEST is expected to lead the emergence of a new marketplace for asset-specific securities providing investors with unique funding alternatives and options for managing risk. Agenus expects to open investment in BEST to qualified investors in mid-February. Terms and conditions of the offering will be described in the company's offering documents at that time. Investor validation and participation will be managed through Atomic Capital's Platform.
The announcement will be made today, in a presentation by Dr. Garo Armen at the Atomic Capital Event: Digital Assets for Professional Investors in New York, NY.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter
About BEST
Biotech Electronic Security Tokens (BEST) are blockchain based securities that will be issued in accordance with Regulation D of the Securities Act of 1933, which will entitle the holder to a defined multiple of the original purchase price upon redemption, that may be claimed starting with the first US commercial sale of the underlying asset.
BEST holders will benefit from downside protection provisions including a capital recall feature allowing them to reclaim a substantial portion of the original purchase price at any time following initial investment while retaining a stake in the security's upside that would result in a "make whole" outcome if the underlying project is successful.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated terms, timing, size and impact of Agenus' potential BEST offering, the potential approval and commercialization of AGEN2034. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Jennifer Buell, PhD
Agenus Inc.
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of Agenus
SOURCE Agenus Inc.
To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Alejandroo Green who wrote () | 3/8/2019 9:25:08 AM | | From: Kirk © | | | | News Release Issued: Mar 8, 2019 (9:00am EST)
To view this release online and get more information about Agenus Bio visit: investor.agenusbio.com
Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., March 8, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, March 14, 2019. In connection with the earnings release, Agenus executives will host a conference call and live webcast at 8:30 a.m. ET the same day to discuss the results and provide Company updates.
Conference Call and Webcast Information:
Date: Thursday, March 14, 2019
Time: 8:30 a.m. ET
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus
Live Webcast: accessible from the Company's website at c212.net or with this link c212.net
A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1 Through AgenTus Therapeutics, a subsidiary of Agenus
SOURCE Agenus Inc. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Kirk © who wrote (116) | 7/13/2019 8:27:35 PM | | From: Rarebird | | | | | Thanks for the post. It served as a reminder to get the first of the two new Shingle's shots, which I did today. I took a Shingles shot 6 years ago, but that one was only supposed to last for 5 years. Last year, I tried to get the new Shingle's shot, but it wasn't in stock at the pharmacy I checked . Since then, I forgot all about it till I read your post. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Rarebird who wrote (117) | 7/15/2019 6:52:46 AM | | From: Rarebird | | | | I feel much better now. I took the Shingrix shot 3pm ( PST) on Saturday. I felt fine the rest of the day. But I woke up Sunday morning with a headache and feeling tired and weak. I pushed myself to go jogging with my dog for an hour. I came back feeling worse. I ran a low grade fever for a few hours. I laid in bed and slept most of the day. Come early evening, I felt a bit better. This morning I am considerably better. I am not tired or weak, slight headache. It is a rough shot. Tylenol helps.
Not looking forward to the second shot. But I will take it. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: Rarebird who wrote (118) | 7/15/2019 10:13:36 AM | | From: Kirk © | | | | That sounds similar to my results.
I got my first Shingrix shot on July 1st around 10 AM. No side effects other than a tiny bit of soreness at the injection site. I used my pole chain saw and heavy duty pruner to cut and prune trees for 1.5 hrs in the afternoon.
July 2nd I felt "off" with sore muscles much like the flu, the injection site was reddish like a bruise and was slightly painful to the touch. I may have been a bit more tired than usual, especially since I had not windsurfed the day before but gardening can cause me to be tired and sore the next day. Running hurts my knees so I did a 1 hr 3.5 mile hike in the afternoon. It didn't seem to slow me down and it was nice to get outside and my mind off feeling a bit sore.
July 3rd I felt great and windsurfed in the afternoon for an hour an 8 minutes covering 13.5 miles with a 3.3 training effect.
July 4th the wind was better and I windsurfed 22.5 miles in 87 minutes with a 3.8 training effect.
My girlfriend had a similar experience with her first and second doses.
I too plan to get the second shot in 4 months after windsurfing season ends so I don't miss a possible good day windsurfing due to the 2nd day flu-like symptoms.
shingrix.com |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Rarebird who wrote (118) | 7/18/2019 2:20:01 PM | | From: Kirk © | | | | Nice hire from a "real company"....
Agenus Appoints Don Vidic as Vice President and Head of Commercial The appointment comes as Agenus is preparing for its first BLA filing in 2020 and evolving towards a commercial company
LEXINGTON, Mass., July 18, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial.
"Don has deep expertise in market access and distribution strategies and shares our commitment to disruptive commercial models designed to provide access to all patients who need our products," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We have built a unique ecosystem which has allowed us to innovate with speed and set new records in drug discovery and development. We are on track to submit our first BLA filing for our lead CTLA-4 and PD-1 molecules in 2020. Our clinical stage next generation CTLA-4 (AGEN1181) and our allogeneic cell therapies are also progressing rapidly. I'm excited to welcome Don to lead our commercial launch efforts at this very exciting time for our company."
Don Vidic is an industry veteran with more than 30 years of expertise in specialty pharma distribution, managed care, as well as physician and pharmacy services. Prior to joining Agenus, Don served as the Chief Pharmacy and Growth Officer at Walgreens Boots Alliance and as the General Manager and VP at McKesson, currently the largest oncology specialty pharma, where he managed all trade, managed care, physician sales and pharmacy services.
"Agenus has an outstanding pipeline of products and a deep commitment to bringing high impact products to patients battling cancer," said Mr. Vidic. "My work has focused on getting patients the products they need, quickly. I will build on the innovative standard Agenus has already set and cut through the current complex networks to get our products to patients and build value for our stakeholders."
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical trial plans and activities and timelines for filing INDs, filing BLAs and initiating commercial launch of candidates, if approved. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of Agenus
News Release Issued: Jul 18, 2019 (2:00pm EDT)
To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com
SOURCE Agenus Inc. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
